Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Figure Technology Solutions Inc. Class A Common Stock (FIGR) vs Neurocrine Biosciences Inc (NBIX) Price & Performance

Figure Technology Solutions Inc. Class A Common StockTrade
Neurocrine Biosciences IncTrade

Price performance (Past 24H)

Key statistics

Figure Technology Solutions Inc. Class A Common Stock vs Neurocrine Biosciences Inc — how do they compare? Figure Technology Solutions Inc. Class A Common Stock trades at $28.68 (market cap $6.19B), while Neurocrine Biosciences Inc trades at $143.97 (market cap $14.36B). The key difference: Neurocrine Biosciences Inc is far larger — about 2.3× Figure Technology Solutions Inc. Class A Common Stock's market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, Figure Technology Solutions Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Figure Technology Solutions Inc. Class A Common Stock for 1 Days and Neurocrine Biosciences Inc for 23 Days on average.

FIGRNBIX
Market Cap
$6.19B$14.36B
Volume
4,762,3421,237,180
Sector
FinancialsHealth
52-Week High
$73.91$185.50
52-Week Low
$24.91$123.10
Typical Hold Time
1 Days23 Days
Enterprise Value
$6.23B$14.37B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Figure Technology Solutions Inc. Class A Common Stock

No Aura AI signal available yet.

Neurocrine Biosciences Inc

Neurocrine Biosciences (NBIX) trades at $142.84, down 0.44% today, with strong fundamental performance including three consecutive quarterly earnings beats and robust profitability metrics. The stock shows bearish technical signals with resistance at $142-145, while maintaining excellent analyst support with 86% buy ratings and a $204 consensus target. Recent developments include pipeline advancements in Prader-Willi syndrome and executive appointments.

NBIX presents a compelling growth story with 20.9% net margins and expanding rare-disease portfolio, though faces execution risks as it diversifies beyond Ingrezza. The 43% upside to consensus target suggests significant potential, but investors must monitor pricing pressures and pipeline execution amid elevated valuation multiples.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

FIGR

No sentiment data available yet.

NBIX
100% Buy0% Sell
Avg holding period · 23 Days

About Figure Technology Solutions Inc. Class A Common Stock

Figure Technology Solutions operates a blockchain-native capital marketplace. Its platform supports loan origination, funding, sale, and trading of tokenized assets, along with digital-asset infrastructure and services.

Read more on FIGR →

About Neurocrine Biosciences Inc

Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.

Read more on NBIX →